AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02591472 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Posttraumatic Stress Disorder (PTSD)
Description: The Posttraumatic Stress Disorder (PTSD) Checklist will be administered to measure posttraumatic stress levels. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
Study NCT02591472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory-II
Description: The Beck Depression Inventory-II is a broadly-applicable, clinically relevant psychometric instrument with high reliability and consistency which notes depression. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
Study NCT02591472 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beck Depression Inventory-II
Description: The Beck Depression Inventory-II is a broadly-applicable, clinically relevant psychometric instrument with high reliability and consistency which notes depression. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
Study NCT02591472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: State-Trait Anxiety Inventory (STAI)
Description: The State-Trait Anxiety Inventory (STAI) will be used to measure state anxiety (anxiety about an event) and trait anxiety (anxiety level as a personal characteristic). This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
Study NCT02591472 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: State-Trait Anxiety Inventory (STAI)
Description: The State-Trait Anxiety Inventory (STAI) will be used to measure state anxiety (anxiety about an event) and trait anxiety (anxiety level as a personal characteristic). This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
Study NCT02591472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tampa Scale of Kinesiophobia-11 (TSK-11)
Description: Tampa Scale of Kinesiophobia-11 (TSK-11) will be used to assess pain-related fear in orthopaedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
Study NCT02591472 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tampa Scale of Kinesiophobia-11 (TSK-11)
Description: Tampa Scale of Kinesiophobia-11 (TSK-11) will be used to assess pain-related fear in orthopaedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
Study NCT03784911 — intervention group
Intervention type: DEVICE
Intervention: SOZO Device
Description: SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. SOZO measurements will be performed before the start of cancer treatment, at the 1/4, 1/2, and 3/4 time points of treatment, and after completion of treatment. Participants be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes.
Study NCT03784911 — intervention group
Intervention type: DEVICE
Intervention: DEXA Scan
Description: DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.
Study NCT02191657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: Oral iron chelator
Study NCT03740139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Police-Mental Health Linkage System
Description: When, during an encounter, the police officer decides to call the number provided in the notice, the Linkage Specialist (a licensed mental health provider from the mental health service where the subject was recruited, who has access to the clinic's EMR) can provide telephonic support to the officer.
Study NCT05193890 — intervention group
Intervention type: GENETIC
Intervention: retrospective analysis of a panel result
Description: retrospective analysis of a exome clinical solution
Study NCT03201744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients will be randomized to moderate (TOF 1-2) or deep (post tetanic count 1-2) relaxation. Low pressure insufflation (start pressure set at 8 mm Hg)
Description: All procedures will start with low insufflation pressure (8 mmHg). Surgical field assessment (scale 1-5) will be performed every 5 minutes (Martini Br J Anaesth 2014). If conditions are poor (rating 1-2), intraperitoneal insufflation will be incrementally increased (10 mmHg, 12 mmHg, 15 mmHg) every 5 minutes as needed.Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
Study NCT02708160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride Free toothpaste
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
Study NCT02708160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride Free toothpaste
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
Study NCT02708160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride Free toothpaste
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
Study NCT02708160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.1% Fluoride toothpaste
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
Study NCT02708160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.1% Fluoride toothpaste
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
Study NCT02708160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1.1% Fluoride toothpaste
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
Study NCT02708160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.243% Fluoride toothpaste
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
Study NCT02708160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.243% Fluoride toothpaste
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
Study NCT02708160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.243% Fluoride toothpaste
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
Study NCT03961581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Using electric car
Description: Child will use little electric cars to go to the reception of operating theatre to operating room.
Study NCT02498860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemebit
Description: 500mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
Study NCT02498860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
Study NCT04221009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI and CBT 4-session manualized intervention
Description: This is a 4-session intervention derived from Motivational Interviewing and Cognitive Behavior Therapy and adapted with cognitive accommodations.
Study NCT02264197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBX 245 CL - fed
Study NCT02264197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBX 245 CL- fasted
Study NCT03192254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-monitoring
Description: recording fruit and vegetable consumption
Study NCT03192254 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self-monitoring
Description: recording fruit and vegetable consumption
Study NCT03192254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: daily monetary incentives
Description: daily payments for consuming fruits and vegetables
Study NCT03192254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: delayed lump sum monetary incentives
Description: lump sum payments for consuming fruits and vegetables
Study NCT03667261 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sealing Socket Abutment
Description: Sealing Socket Abutment (SSA) serves as a mechanical barrier to isolate the grafted area, stabilize the clot and contain the graft material, and seal the socket from foreign contaminants and also minimizing the risk of premature loading of the implant during healing. By preparing an SSA fabricated to follow the transmucosal contours of the natural tooth, the grafted area can be sealed and separated from the growth of soft tissue without the use of a membrane or releasing incisions
Study NCT03667261 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cover screw
Description: immediate implant placement in mandibular molar area will be covered with conventional cover screw
Study NCT00572702 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal fixation Amreich-Richter
Description: Descending vaginal cuff will be treated with fixation of the cuff on sacrospinous ligament
Study NCT00572702 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prolift total
Description: Descending vaginal cuff will be treated with insertion of site-specific mesh into the vesico-vaginal and recto-vaginal space
Study NCT01779401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75mg
Study NCT01779401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 150mg
Study NCT01779401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100mg
Study NCT01314456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviGo
Description: Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate.
Study NCT01779401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 100mg
Study NCT03695250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDO1 Inhibitor BMS-986205
Description: Given PO
Study NCT03695250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02906059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Study NCT02906059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT04388189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: FDA approved antidepressant
Study NCT04992000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4-free app + PHN intervention
Description: same mentioned in groups
Study NCT04388189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: FDA approved antidepressant
Study NCT02498314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grade I-II SZ mobilization
Description: Hip grade I-IISZ traction in a resting position is applied using gentle repetitive traction movements during 10 minutes. The mean peak force applied is 2,71N (S.D= 0,94), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
Study NCT02498314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grade II TZ mobilization
Description: Hip grade IITZ traction in a resting position is applied during 10 minutes. The traction force is applied during 45 seconds with 15 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 5.94 N (S.D= 1), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
Study NCT02498314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grade III mobilization
Description: Hip grade III traction in a resting position is applied during 10 minutes. The traction force is applied during 30 seconds with 30 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 7.04 N (S.D= 0.32), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
Study NCT00990236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin dose adjusted Lovenox based on TEG
Description: Enoxaparin doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R \< 1.0 min - increase dose by 10 mg BID; delta-R >/= 1.0 min and \</= 2.0 min - no change; delta-R > 2.0 min - decrease dose by 10 mg BID.
Study NCT00990236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 30 mg BID
Description: Enoxaparin dose of 30 mg twice a day without any adjustments
Study NCT01489488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (BAY63-2521)
Description: Single oral dose of 2.4 milligram (mg) riociguat (BAY63-2521) as pediatric high-concentration suspension (0.15 mg per milliliter \[mg/mL\], i.e. 16 mL) under fasting conditions
Study NCT00058773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion of EBV Specific Cytotoxic T-Lymphocytes
Description: EBV specific cytotoxic T-lymphocytes will be given by intravenous injection over 1-10 minutes.~Each patient will receive two injections, 14 days apart.
Study NCT04270890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abdominal compression belt system
Description: The abdominal compression belt system is provided free of charge from CDR systems, Canada.~The belt has specifically been chosen from other similar devices commercially available as it is independent of other immobilisation devices and can be used with the patient located within a full body vacbag as per current immobilisation position.
Study NCT03351140 — intervention group
Intervention type: OTHER
Intervention: Qualitative Interviews
Description: Subjects will participate in a qualitative interview lasting up to 90 minutes. The interviews will include a concept elicitation component to explore details of the subject's perceived disease condition, functional limitations and impacts on daily life and health-related quality-of-life (HRQoL). In addition, a card sorting exercise will be used to evaluate the relevance and comprehension of PROMIS Physical Function items.
Study NCT03351140 — intervention group
Intervention type: OTHER
Intervention: PROMIS Physical Function Items
Description: PROMIS Physical Function Items is a set of self-report measurement tools. The latest version of PROMIS Physical Function Items contains 165 items for self-assessment. PROMIS Physical Function Cancer Item Bank contains a subset of 45 items relevant to cancer subjects. Subjects will complete half of the PROMIS Physical Function Items during their enrollment visit and the other half of items prior to their interview.
Study NCT04776720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Practice Program
Description: 3 month group yoga classes
Study NCT04776720 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Conditioning Program
Description: 3 month group physical conditioning classes
Study NCT02988947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNE+HyP
Description: This is a combined PNE and Hypnosis psychological intervention. PNE is a cognitive based approach that highlights the biopsychosocial model of pain and focuses on neurophysiological and neurobiological processes and pain representation. Hypnosis aims at promoting pain control, increasing positive coping strategies, and targeting positive psychological variables.
Study NCT02371460 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA-rich algal oil
Description: Mothers will receive a DHA-rich algal oil treatment (400 mg DHA per capsule) three times a day before meals from randomization (\<72 hours post-delivery) until the infant reaches 36 weeks PMA.
Study NCT02371460 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mothers will receive a placebo capsule three times a day before meals from randomization (\<72 hours post-delivery) until the infant reaches 36 weeks PMA.
Study NCT02723552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 40 minute aerobic exercise sessions 3x/week.
Study NCT02177734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N9 vaccine GSK3277510A
Description: One dose of GSK3277510A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277510A H7N9 vaccine administered IM in the deltoid region of dominant arm at Day 21
Study NCT02177734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational H7N9 vaccine GSK3277509A
Description: One dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of dominant arm at Day 21
Study NCT02177734 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of placebo administered IM at the deltoid region of dominant arm at Day 21
Study NCT02058550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Receive reminder email survey
Study NCT02058550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer-assisted intervention
Description: Receive reminder email survey
Study NCT02604368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC411
Description: Soft gelatin capsule
Study NCT02604368 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soft gelatin capsule
Study NCT02207049 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Snacking
Description: Snacks will be provided to preschoolers, either as part of total caloric needs or above total caloric needs
Study NCT02207049 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Snacking
Description: Caloric needs will be provided to preschoolers within three meals
Study NCT02274935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Balance and gait exercise twice a week for an hour
Study NCT04209634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: Single loading intravenous (IV) dose on day 1, then fixed doses sub-cutaneous (SC) (based on body weight) QW (±2 days) over the treatment period.
Study NCT05252013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Bean Hull Bread
Description: The bean hull bread will deliver 21.96 g of fibre. Volunteers will consume a roll of bean hull bread (155g/portion) served with 25g of raspberry jam.
Study NCT05252013 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Experimental: Plain Bread
Description: The control bread will deliver 4.53 g of fibre. Volunteers will consume a roll of plain bread (122g/portion) served with 25g of raspberry jam.
Study NCT02269553 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMJ(TM) NextGeneration
Description: The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts.